Longevity technology and preventive health is one of the fastest-growing segments in health technology – driven by ageing populations, rising chronic disease burden, and growing consumer willingness to invest in health optimisation. Longevity clinics, biomarker testing companies, health coaching platforms, and preventive health technology providers are all expanding globally. GreyRadius helps longevity and preventive health businesses validate consumer and corporate buyer demand, navigate regulatory requirements, execute GTM plans, and raise capital.
Why now? The Gulf's Vision programmes, Singapore's Healthier SG strategy, and India's preventive health push are all creating significant institutional demand for longevity and preventive health solutions. High-net-worth consumers in the Gulf and Southeast Asia are willing to pay premium prices for evidence-based longevity programmes. The market is forming now – before mass-market adoption arrives.
The global longevity market is projected to reach $610B by 2025 growing at 6% annually – with preventive health, biomarker testing, and personalised nutrition representing the fastest-growing segments.
Corporate wellness is becoming a serious longevity investment channel – employers in Singapore, the Gulf, and India are investing in employee longevity programmes as productivity and retention tools.
The convergence of wearables, genomics, and AI is enabling unprecedented personalisation of longevity interventions – companies that can combine biomarker data with behavioural coaching are achieving the highest retention.
High-net-worth individuals in the Gulf and Southeast Asia are allocating significant personal healthcare spending to longevity clinics, executive health programmes, and preventive diagnostics – often travelling internationally for access.
If you recognise your situation below, we can help.
Consumer demand validation
You need to validate that consumers in your target market are interested in longevity interventions – and what price points, programme formats, and evidence requirements they need.
Corporate buyer strategy
You need to identify and approach corporate wellness buyers – HR directors, benefits managers, and executive health programme owners – who are actively procuring longevity solutions.
Regulatory pathway mapping
You need to understand how your longevity product is regulated – as a supplement, medical device, diagnostic test, or wellness service – in your target market.
GTM for a longevity clinic or platform
You have a longevity programme, biomarker testing service, or health optimisation platform and need a go-to-market strategy covering both B2C and B2B channels.
Raising capital for a longevity venture
You are raising investment and need a pitch book grounded in consumer demand data, clinical evidence, and a credible growth model.
Clinical and wellness partner identification
You need to identify hospital systems, corporate wellness programmes, and health insurers as distribution channels in your target market.
Every engagement is grounded in primary research and delivers a measurable outcome.
Validate consumer and corporate buyer demand for your longevity product in a new market. Covers HNW consumer surveys, corporate wellness buyer interviews, regulatory mapping, and a Go/Defer/Kill recommendation.
Learn more →Full financial and operational feasibility for longevity clinic and platform investments. Covers consumer demand modelling, corporate channel sizing, revenue model, and investor-ready projections.
Learn more →End-to-end market entry for longevity companies. Regulatory pathway, clinical partner identification, corporate wellness channel development, and first-client acquisition.
Learn more →Embedded GTM team for longevity platforms. HNW consumer outreach, corporate wellness pipeline, and first-programme or first-subscription milestone tracking.
Learn more →Investor-ready pitch books for longevity ventures. Consumer-demand-validated market sizing, clinical evidence narrative, and investor identification across healthtech and longevity-focused VC.
Learn more →AI use-case prioritisation in longevity – from biomarker analysis and personalised intervention design to health trajectory prediction and automated coaching.
Learn more →80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
HealthTech · Market Entry
HealthTech · GTM
HealthTech · Assessment
All three. We work with longevity clinics on market entry and feasibility, digital platforms on GTM and market entry, and longevity biotech companies on fundraising.
Gulf, Southeast Asia, South Asia, and Europe – markets where HNW consumer spending on preventive health is highest and corporate wellness investment is growing.
Typically 6–10 weeks for consumer demand research, regulatory mapping, and market entry strategy.
Yes. Corporate wellness buyer identification and initial commercial conversations are part of our GTM Execution-as-a-Service.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Gulf, Southeast Asia, South Asia, Europe.
